TSE:4502Pharmaceuticals
Takeda Pharmaceutical (TSE:4502) After Psoriasis Data And FDA Filing Plans Still Looks Undervalued
Takeda Pharmaceutical (TSE:4502) is back in focus after releasing new Phase 3 data for its oral TYK2 inhibitor zasocitinib in moderate to severe plaque psoriasis, alongside plans for a US FDA filing.
See our latest analysis for Takeda Pharmaceutical.
The zasocitinib update comes after a solid run in Takeda Pharmaceutical’s shares, with a 1-month share price return of 10.98% and year to date share price return of 11.47%. The 1-year total shareholder return of 31.40% and 5-year total...